Foresite Capital Management Ii LLC Continues to Hold Holding in Insmed Incorporated (INSM)

April 22, 2018 - By Kurt Siggers

Insmed Incorporated (NASDAQ:INSM) LogoInvestors sentiment decreased to 1 in Q4 2017. Its down 2.74, from 3.74 in 2017Q3. It is negative, as 27 investors sold INSM shares while 40 reduced holdings. 18 funds opened positions while 49 raised stakes. 73.21 million shares or 49.25% less from 144.25 million shares in 2017Q3 were reported. Prudential accumulated 7,320 shares. Citigroup reported 65,397 shares or 0% of all its holdings. Wellington Management Grp Llp holds 0% or 81,758 shares. Bp Public Ltd Company stated it has 12,276 shares or 0.01% of all its holdings. D E Shaw & Company Incorporated accumulated 507,325 shares. Orbimed Ltd Liability reported 1.50M shares. Hbk Investments LP owns 46,275 shares for 0.01% of their portfolio. Morgan Stanley stated it has 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Qs Invsts Lc owns 75,620 shares or 0.02% of their US portfolio. Adage Prtnrs Grp Inc Ltd Liability Co has 0.05% invested in Insmed Incorporated (NASDAQ:INSM) for 720,034 shares. Rhumbline Advisers holds 0% or 74,574 shares in its portfolio. Metropolitan Life Ny has invested 0.01% in Insmed Incorporated (NASDAQ:INSM). Quantbot Lp has 0% invested in Insmed Incorporated (NASDAQ:INSM). Gemmer Asset Mgmt Lc holds 0% or 3 shares in its portfolio. State Of Wisconsin Inv Board stated it has 0.01% in Insmed Incorporated (NASDAQ:INSM).

Jim Tanenbaum increased its stake in Insmed Incorporated (INSM) by 72.88% based on its latest 2017Q4 regulatory filing with the SEC. Foresite Capital Management Ii Llc bought 218,645 shares as the company’s stock declined 30.16% with the market. The hedge fund run by Jim Tanenbaum held 518,645 shares of the health care company at the end of 2017Q4, valued at $16.17M, up from 300,000 at the end of the previous reported quarter. Foresite Capital Management Ii Llc who had been investing in Insmed Incorporated for a number of months, seems to be bullish on the $1.80B market cap company. The stock increased 1.77% or $0.41 during the last trading session, reaching $23.52. About 328,456 shares traded. Insmed Incorporated (NASDAQ:INSM) has risen 31.10% since April 22, 2017 and is uptrending. It has outperformed by 19.55% the S&P500.

Foresite Capital Management Ii Llc, which manages about $286.24M US Long portfolio, decreased its stake in Aimmune Therapeutics Inc. by 720,316 shares to 3.10M shares, valued at $117.25M in 2017Q4, according to the filing.

Insmed Incorporated (NASDAQ:INSM) Ratings Coverage

Among 5 analysts covering Insmed (NASDAQ:INSM), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Insmed had 8 analyst reports since October 30, 2017 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, January 4 report. The rating was maintained by Robert W. Baird on Monday, October 30 with “Buy”. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, November 2. The company was upgraded on Thursday, January 4 by Stifel Nicolaus. The stock has “Buy” rating by H.C. Wainwright on Monday, November 6. The firm has “Buy” rating given on Thursday, January 4 by Robert W. Baird. As per Wednesday, March 14, the company rating was maintained by Leerink Swann.

Insmed Incorporated (NASDAQ:INSM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.